Chemiluminescence immunoassay (CLIA) has been widely applied in different fields including environmental monitoring, liquid chromatography, clinical diagnosis; food safety, pharmaceutical analysis, immuno-and gene probe assays, as a promising approach for selective, sensitive, rapid and simple analysis. It is often necessary to detect a large number of complicated or low-abundance samples. However, traditional methods need great consumption of time, reagents and labor, which limit their clinical applications. As a result, rapid, high-throughput, sensitive and low-cost detection methods have become the development trend of CLIA. A new chemiluminescence immunoassay analyzer with advanced acridinium ester (AE) technology will be installed at the radioimmunoassy laboratory of National Institute of Nuclear Medicine and Allied Sciences (NINMAS) shortly. In conjunction with the existing Radioimmunoassay (RIA), Immunoradiometric assay (IRMA) and DissociationEnhanced Lanthanide Fluorescent Immunoassay (DELFIA), introduction of chemiluminescence immunoassay (CLIA) technology will expand the activities of in vitro immunoassay. It will also improve the research and development activities of in vitro division of NINMAS. In this review article, we have summarized the basic principle of chemiluminescence immunoassay and its applications. A comparison of RIA, CLIA and enzyme-linked immunosorbent assay (ELISA) was also briefly described in the article.
INTRODUCTION
Luminescence is the most conveniently defined as the radiation emitted by a molecule, or an atom, when these species return to the ground state from the exited state.
According to the source of excitation, luminescence Immunoreaction is the recognition between antigen and antibody. Because of the low diffusion rate of these large molecules and the site block problem, the immunoreaction rate controlled by mass transport and reaction kinetics is generally low. Conventional immunoassay always needs a long incubation time, which in turn causes the whole analysis to take several hours for completion, so the throughput and application range are largely limited (7).
Researchers have designed different methods to shorten the analysis time by improving mass transport and reaction kinetics. The rapid immunoassay has expanded the applications of CLIA.
Traditionally, immunoassay is performed as discrete tests, i.e., one analyte per assay run, and several runs are needed to detect all the components in a complex system. Great consumption of time, reagents and labor limits the application of the traditional strategy. Since a multianalyte immunosensing system has the advantages of high throughput, short time, low consumption and low cost, it has been very popular during the recent years. It is also necessary to detect samples of low abundance, so developing highly sensitive CLIA has become a new trend. The main approach to improving the analysis sensitivity is to reduce the noise and enhance the signal. In order to reduce the noise, small proteins are always used to block the active site on the biosensing interface. Signal amplification techniques focus on constructing functionalized interface and designing novel trace tags (7). 
CHEMILUMINESCENCE IMMUNOASSAY (CLIA)
CLIA is a method to determine the concentration of samples according to the intensity of the luminescence that the chemical reaction emits. In general, chemiluminescence reaction yields one of the reaction products in an electronic excited state producing light on falling to the ground state. As can be seen in Figure  3 , the process of light emission in chemiluminescence is the same as in photoluminescence, except for the excitation process. In fluorescence and phosphorescence, the electronically excited state is produced by absorption of UV-visible light returning to the ground state (S 0 ) from the lowest singlet excited state (S 1 ) or from the triplet excited state (T 1 ) (8, 9) . In general, a chemiluminescent (CL) reaction can be generated by two basic mechanisms ( Figure 4 ) in a direct reaction, two reagents, usually a substrate and an oxidant in the presence of some cofactors, react to from a product or intermediate, sometimes in the presence of a catalyst. Then some fraction of the product or intermediate will be formed in an electronically excited state, which can subsequently relax to the ground state with emission of a photon. The substrate is the CL, precursors, which is converted into the electronically excited molecule, responsible for light emission or acting as the energy as transfer donor in indirect CL. The most popular CL substrates are luminol, isoluminol and their derivatives, acridinium ester derivatives, peroxidase and alkaline phosphatase (7) . On the contrary, indirect or sensitized CL is based on a process of transfer of energy of the excited specie's to a fluorophore (10). This process makes it possible for those molecules that are unable to be directly involved in CL reaction to transfer their excess of energy to a fluorophore that in turn is excited, releasing to its ground state with photon emission. All of these paths lead to a great variety of practical uses of CL in solid, gas, and liquid phases (11). However, it has become apparent that the association of luminol with protein can drastically affect the quantum yield of the reaction. This is evidenced by work with derivatives of isluminol, in particular Aminobutylethyl isoluminol (ABEl), which can be coupled to low molecular weight compounds without loss in quantum yield (13) and related molecules have been used as labels for a variety of steroid immunoassays which have levels of performance comparable to those of the corresponding radioimmunoassays (14). A similar loss in quantum yield was observed when aminohexylethyl isoluminol was used to label antibodies to hepatitis B surface antigen (12) .
The use of acridinium ester derivatives ( Figure 5 ), such as DMAE, NSP-DMAE, HEGAE (www.siemens.disgnodtics)), HQYAE (15), ZAE (16) etc., have potential advantages as compared with luminol derivatives and can be explained with the figure 6, which summarizes their light-emitting reactions. Both reactions are oxidative and occur in alkaline conditions, though in the case of luminol, there is the absolute requirement for a catalyst. This can be a simple transition metal cation such as Mn ++ or Ni ++ but may also be a complex macromolecule such as horseradish peroxidase and cytochromes (17) . The most popular catalyst is microperoxidase since this yields an efficient reaction under relatively mild conditions. This requirement for a catalyst renders the reaction susceptible to interference from materials present in biological samples while the powerful oxidizing conditions may result in high background effects (12) .
In contrast, the mild conditions required for acridinium ester reactions produce relatively low background chemiluminescence. Moreover, the reaction itself involves an oxidative cleavage to yield a dioxetanone intermediate before the formation of the excited product molecule N methyl acridone ( Figure 7) . As a result of the cleavage the N-methyl acridone is dissociated prior to the light emission so that quenching by associated protein is avoided (15) . IRMA is an alternative procedure to RIA, which used the same type of immunological reaction but was based on a different principle. RIA technique involves competition between labeled antigen and unlabeled antigen (as standards or unknowns) for a limited number of antibody binding sites, whereas, IRMA relies on the conversion of antigen to a labelled derivative by reaction with labeled antibody. The derivative is then measured directly. The main advantage of IRMA is that performance is optimal when excess-labeled antibody is used, the consequence being that all antigen is rapidly derivatized. These rapid reaction kinetics contrasts with those seen in RIA where high sensitivity is achieved by diluting out the antibody with the result that extended reaction times may be required to provide the desired sensitivity. CLIA offers distinct advantages over RIA. First and foremost, they eliminate the use of radioactive labels and the concomitant concerns regarding exposure of personnel to radiation and waste disposal. In addition, these assays use reagents with a longer shelf life, a higher sensitivity, and a shorter running time (18) . The estradiol RIA, for example, uses estradiol labeled with 125I and has a shelf life of only 2 months because of the short half-life of 125 I.
Also, iodinated steroids tend to have a higher binding affinity for the antibody than the natural steroid, thus decreasing the detection sensitivity of the assay. While RIA requires 1-3 hours incubation time and then 1 minute per tube for quantification, a CLIA using acridinium esterlabeled estradiol requires only 30 minutes for incubation and only 5 seconds for quantification (18) . Avner Hershlag et al 2000 (18) reported that in case of patients receiving gonadotropins for ovarian stimulation, CLIA results for estradiol correlated closely with RIA results. However, in patients receiving oral estradiol to prepare the endometrium for transfer of frozen embryos, marked discordance was observed between CLIA and RIA values of estradiol.
A two-site immunochemiluminometric assay (ICMA) methodology ( Figure 8 ) to yield highly sensitive assay for human thyroid stimulating hormone (TSH) is at present under evaluation (19) . In this assay, the analyte is reacted either sequentially or simultaneously with labeled antibodies and solid-phase antibodies. In this procedure, the uptake of labelled antibody on to solid-phase antibody is a function of the quantity of analyte bound and hence the analyte concentration in the sample.
Figure 7: Two-site immunochemiluminometric assay (ICMA) of human thyrotropin (TSH)
In this procedure standards or serum samples (100 µL) are reacted with a monoclonal antibody (100 µL, 1.5 ng) labelled with 3 mol/mol acridinium ester. After 2 h, solid-phase antibody suspension (100 µL, 50 µg) is added and after a further 1 h, 1mL of buffer is added and the mixture centrifuged. After one further 1mL wash, the chemiluminescent activity associated with the solid-phase is quantified luminometrically following injection of 200 µL water to resuspend the pellet followed by 200 µL 0.1% (v/v) H 2 O 2 in 0.1M NaOH.
The photon counts are integrated over a 2 s period and the bound counts related to the dose of analyte present. The use of reagent excess methodology together with an acridinium ester label of high specific activity combines to make this the most sensitive immunoassay yet described for TSH (20 Chen CK et al 1996 (23) evaluated the performance of chemiluminescent immunoassay (CLIA) system (Immulite, Diagnostic Products Corp, Los Angeles, CA, USA) and compared it with a popular Immunoradiometric immunoassay (IRMA) system. In that study, the data of 158 patients whose thyroid function was assessed and that of another 158 patients whose parathyroid function was assessed were analyzed. The thyroid-stimulating hormone (TSH) CLIA is an ultrasensitive TSH (us-TSH) assay that provided more detailed, reliable results for low TSH concentrations than TSH IRMA. Coupled with the free-T4 assay, the us-TSH assay enhanced the ability to detect and monitor the status of thyroid dysfunction. Intact-parathyroid hormone (PTH) CLIA detected lower serum intact-PTH levels, was found more sensitive and as reliable as IRMA.
Jing Hua et al 2005 (24) compared the characteristics of chemiluminescent immunoassay (CLIA), radioimmunoassay (RIA) and magnetic solid phase enzyme-linked immnosorbent assay (MSP-ELISA) in measuring thyroid hormones, total T3, total T4, FT3, FT4 and TSH in human serum and standard samples of thyroid hormones by CLIA, RIA and MSP-ELISA respectively. No statistical differences between CLIA, RIA and MSP-ELISA in linearity and relativity were reported. CLIA was better than RIA and MSP-ELISA in precision and accuracy.
The concentration of carcinoembryonic antigen (CEA) in serum obtained from different carcinosis patients was detected by using the method of double antibody sandwich CL immunoassay and the results obtained by this method are fairly well agreeable to those obtained by RIA method (25) . The α-fetoprotein (AFP) is the most widely used tumor marker, consistently can be measured through CLIA for the diagnosis of Hepatocellular carcinoma (26, 27) .
Prostate cancer (PCa) has become a most widespread and stubborn disease and a major cause of death in the old age male population nowadays. Zheng Y et al 2008 (28) development sensitive chemiluminescence immunosensor for the detection of PSA. Most of the current PSA detection methods are usually based on immunoassays and CLIA is among the most widely used readout modality in virtue of undoubted advantages over other more widely used systems including enzyme-linked immunosorbent assays (ELISA), time-resolved immunofluorometric assay, surface plasmon fluorescence immunoassay, bioluminescent immunoassay, electrochemical and surface enhanced Raman scattering (SERS) (29) . The high detectability and rapidity of CL techniques, along with the availability of microarray-based analytical devices, allows the development of high throughput screening assays, in which simultaneous, multi-analyte detection is performed on multi sample. Therefore, more and more medical experts and chemists are interested in CLIA. However, the development of CLIA is dependent on the application of the sensitive and selective chemiluminescent probe. Improvements in analytical sensitivity will likely lead to the discovery of new analytes tumours detection. Technical enhancement holds the promise of detecting very low concentrations in serum using nanoparticles as labels and CL detection (31, 32) .
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) AND CLIA

CONCLUSION
Chemiluminescence immunoassay offers a viable and logical alternative to a range of analytical immunoassay based on the use of radioisotopes. Its feasibility has been demonstrated for a range of analytes including both high and low molecular weight species. The stability of the reagents and their analytical performance has important implications in improving and maintaining high quality assay performance. Most importantly the development of ICMA technology based on labelled antibodies has the potential for increasing assay sensitivity. It is likely that this technology will prove valuable in the detection and monitoring of infective agents as well as tumour markers where conventional immunoassay technology provides insufficient sensitivity. 
